PARIS--(BUSINESS WIRE)--Regulatory News:BioAlliance Pharma SA (Euronext Paris: BIO), a Company dedicated to orphan oncology products and specialty products, today announces the receivability of Sitavig® (Sitavir® in Europe) US registration dossier from the Food and Drug Administration(FDA) for the treatment of recurrent orofacial herpes.
